Aura Biosciences announced that CEO Natalie Holles will participate in the Stifel 2026 Healthcare Conference on November 10, 2026, discussing their innovative ocular cancer therapy, Bel-sar. Bel-sar is a first-in-class treatment designed to preserve vision while targeting ocular tumors through tumor necrosis and immune activation. The company has fully enrolled its Phase 3 study for early choroidal melanoma and continues research on other ocular cancers. This presentation highlights Aura's progress and commitment to improving outcomes for patients with ocular cancers.
Aura Biosciences' upcoming participation in the Stifel 2026 Healthcare Conference provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 92 rose and 55 fell today. Notable movers include TWST (Twist Bioscience Corp) at USD 139.50 with a 1-day change of +8.11% and Pluang order activity of 38% Sell / 62% Buy, WGS (GeneDx Holdings Corp) at USD 68.89 with +7.49% change and 66% Sell / 34% Buy order split, and SMMT (Summit Therapeutics Inc) at USD 15.86 with +7.09% change and 0% Sell / 100% Buy order activity. Typical hold times on Pluang range from 18 to 27 days among these movers.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
Postal Realty Trust, Inc. announced a net income of $0.16 per diluted share for Q3 2026, driven by acquisitions of 145 USPS properties worth $82 million and a 25.2% increase in rental income year-over-year. The company raised its 2026 acquisition gui...
Crescent Biopharma awarded stock options for 11,775 shares to a new non-executive employee as part of an inducement plan approved by its Compensation Committee. The options have a 10-year term with an exercise price of $12.91, matching the closing sh...
HP Inc. will announce its financial results for the fourth quarter and full fiscal year ending October 31, 2026, on November 24, 2026, via a live webcast. The company will also participate in several investor conferences in December, including UBS Gl...
